Tronconi M, Colombo A, De Cesare M, Marchesini R, Woodburn K W, Reiss J A, Phillips D R, Zunino F
Department of Health Physics, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy.
Cancer Lett. 1995 Jan 6;88(1):41-8. doi: 10.1016/0304-3835(94)03612-m.
In an attempt to identify novel compounds useful for the optimization of Photodynamic Therapy (PDT), the tissue localization of new synthetic porphyrins was compared with Photofrin II in nude mice xenografted with a human small cell lung cancer (POVD). Three haematoporphyrin analogues were selected for this study based on prior in vitro photosensitivity screening of a series of 15 such derivatives, as well as on the basis of improved localization in C6 gliomas in mice. Two of the porphyrins yielded better tumour:normal lung ratios than Photofrin II and, of these two, one (P13) is known to exhibit good photosensitization properties both in vitro and in vivo, and is therefore a good candidate as a lead compound for the development of porphyrins suitable for the photodynamic treatment of lung tumours.
为了鉴定可用于优化光动力疗法（PDT）的新型化合物，将新合成卟啉与光敏素II在移植了人小细胞肺癌（POVD）的裸鼠中的组织定位进行了比较。基于对一系列15种此类衍生物的体外光敏性预筛选，以及在小鼠C6胶质瘤中定位改善的基础，选择了三种血卟啉类似物进行本研究。其中两种卟啉产生了比光敏素II更好的肿瘤与正常肺的比值，并且在这两种中，一种（P13）已知在体外和体内均表现出良好的光敏性质，因此是开发适用于肺肿瘤光动力治疗的卟啉的先导化合物的良好候选者。
